FibroGen Inc

19.73-0.1600-0.80%Vol 2.22M1Y Perf -44.07%
Apr 13th, 2021 16:00 DELAYED
BID19.01 ASK19.60
Open19.21 Previous Close19.89
Pre-Market- After-Market19.40
 - -  -0.33 -1.67%
Target Price
42.00 
Analyst Rating
Moderate Buy 1.86
Potential %
112.87 
Finscreener Ranking
★★     46.95
Insiders Trans % 3/6/12 mo.
-100/-100/-75 
Value Ranking
★★     46.90
Insiders Value % 3/6/12 mo.
-100/-100/-65 
Growth Ranking
★★★     54.75
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-58 
Income Ranking
 —    -
Market Cap1.81B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
4.12 
Earnings Date
6th May 2021

Today's Price Range

18.8019.87

52W Range

18.1257.21

5 Year PE Ratio Range

-31.40-20.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.05%
1 Month
-43.87%
3 Months
-54.18%
6 Months
-57.91%
1 Year
-44.07%
3 Years
-58.94%
5 Years
-3.09%
10 Years
-

TickerPriceChg.Chg.%
FGEN19.73-0.1600-0.80
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
4.50
4.60
0.06
0.09
-77.70
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
95.00
-189.40
-171.40
-62.40
-68.65
RevenueValueIndustryS&P 500US Markets
151.92M
1.66
11.45
3.34
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.29-0.64-120.69
Q03 2020-0.890.35139.33
Q02 2020-0.59-0.95-61.02
Q01 2020-0.30-0.89-196.67
Q04 2019-0.62-1.12-80.65
Q03 2019-0.59-0.573.39
Q02 2019-0.491.26357.14
Q01 2019-0.68-0.5322.06
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.79-464.29Negative
6/2021 QR-0.4133.87Positive
12/2021 FY-1.51-93.59Negative
12/2022 FY-2.44-121.82Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.79
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume2.22M
Shares Outstanding91.56M
Trades Count18.13K
Dollar Volume43.52M
Avg. Volume1.43M
Avg. Weekly Volume7.43M
Avg. Monthly Volume2.62M
Avg. Quarterly Volume1.54M

FibroGen Inc (NASDAQ: FGEN) stock closed at 19.73 per share at the end of the most recent trading day (a -0.8% change compared to the prior day closing price) with a volume of 2.22M shares and market capitalization of 1.81B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 531 people. FibroGen Inc CEO is Enrique A. Conterno.

The one-year performance of FibroGen Inc stock is -44.07%, while year-to-date (YTD) performance is -46.81%. FGEN stock has a five-year performance of -3.09%. Its 52-week range is between 18.12 and 57.21, which gives FGEN stock a 52-week price range ratio of 4.12%

FibroGen Inc currently has a PE ratio of -8.80, a price-to-book (PB) ratio of 4.08, a price-to-sale (PS) ratio of 11.99, a price to cashflow ratio of 20.70, a PEG ratio of 2.32, a ROA of -21.51%, a ROC of -40.80% and a ROE of -38.47%. The company’s profit margin is -68.65%, its EBITDA margin is -171.40%, and its revenue ttm is $151.92 Million , which makes it $1.66 revenue per share.

Of the last four earnings reports from FibroGen Inc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.79 for the next earnings report. FibroGen Inc’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for FibroGen Inc is Moderate Buy (1.86), with a target price of $42, which is +112.87% compared to the current price. The earnings rating for FibroGen Inc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

FibroGen Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

FibroGen Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 22.25, ATR14 : 3.00, CCI20 : -134.49, Chaikin Money Flow : -0.44, MACD : -6.12, Money Flow Index : 20.89, ROC : -37.01, RSI : 30.52, STOCH (14,3) : 8.94, STOCH RSI : 0.97, UO : 24.75, Williams %R : -91.06), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of FibroGen Inc in the last 12-months were: Elias Kouchakji (Option Excercise at a value of $103 220), Enrique A. Conterno (Buy at a value of $988 882), James A. Schoeneck (Option Excercise at a value of $130 050), K. Peony Yu (Option Excercise at a value of $180 000), K. Peony Yu (Sold 20 052 shares of value $937 686 ), Kalevi Kurkijarvi (Option Excercise at a value of $400 481), Kalevi Kurkijarvi (Sold 17 999 shares of value $814 863 ), Pat Cotroneo (Option Excercise at a value of $922 617), Pat Cotroneo (Sold 47 624 shares of value $2 270 018 ), Roberto Pedro Rosenkranz (Option Excercise at a value of $457 200), Thomas F. Kearns (Option Excercise at a value of $63 000), Thomas F. Kearns (Sold 18 000 shares of value $630 360 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (57.14 %)
4 (50.00 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (42.86 %)
4 (50.00 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.86
Moderate Buy
2.00
Moderate Buy
1.67

FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

CEO: Enrique A. Conterno

Telephone: +1 415 978-1200

Address: 409 Illinois Street, San Francisco 94158, CA, US

Number of employees: 531

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

68%32%

Bearish Bullish

46%54%

Bearish Bullish

52%48%

News

Stocktwits